A Study of CS1003 in Subjects With Advanced Solid Tumors
This study will evaluate the safety, tolerability, pharmacokinetic profile and treatment effect of a new drug known as CS1003 in patients with advanced tumors.
Advanced Cancer
BIOLOGICAL: CS1003|BIOLOGICAL: CS1003|DRUG: Regorafenib
Number of participants with adverse events, From the day of first dose to 30 days after last dose of CS1003
Area under the plasma concentration-time curve (AUC), From the day of first dose to 30 days after last dose of CS1003|Maximum plasma concentration (Cmax), From the day of first dose to 30 days after last dose of CS1003|Time to reach maximum plasma concentration (Tmax), From the day of first dose to 30 days after last dose of CS1003|Terminal elimination half-life (t1/2), From the day of first dose to 30 days after last dose of CS1003|Disease assessment by CT/MRI scan, To be performed every 9 weeks during treatment period (up to 2 years) and within 30 days after last dose of CS1003|Anti-CS1003 antibody, From the day of first dose to 30 days after last dose of CS1003
This study will evaluate the safety, tolerability, pharmacokinetic profile and treatment effect of a new drug known as CS1003 in patients with advanced tumors.